An evidence-based hypothesis for beneficial effects of telmisartan on Marfan syndrome

International Journal of Cardiology

Volumn 158, Issue 1, 2012, Pages 101-102

  Takagi, Hisato ^a   Yamamoto, Hirotaka ^a   Iwata, Kotaro ^a   Goto, Shin Nosuke ^a   Umemoto, Takuya ^a  

^a SHIZUOKA MEDICAL CENTER   (Japan)

Author keywords

Hypothesis; Losartan; Marfan syndrome; Proliferation activated receptor gamma; Telmisartan; Transforming growth factor beta

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; COLLAGEN TYPE 4; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRILLIN 1; G PROTEIN COUPLED RECEPTOR; LATENCY ASSOCIATED PEPTIDE; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; LOSARTAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; TELMISARTAN; THROMBOSPONDIN 1; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; VALSARTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CELL ACTIVATION; CELL GROWTH; CELL MIGRATION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE CONTROL; DOSE RESPONSE; DOWN REGULATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; ECTOPIA LENTIS; ENZYME ACTIVATION; ENZYME INHIBITION; EVIDENCE BASED PRACTICE; FBN1 GENE; GENE; GENE FUNCTION; GENE MUTATION; GLOMERULOSCLEROSIS; KIDNEY INJURY; LETTER; MARFAN SYNDROME; MECHANICAL STRESS; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN SECRETION; RISK BENEFIT ANALYSIS; SIGNAL TRANSDUCTION; TGFBR1 GENE; TGFBR2 GENE; TRANSCRIPTION INITIATION; TREATMENT RESPONSE; UPREGULATION;

EID: 84862000541     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2012.03.051     Document Type: Article

References (32)

1. H. Kakuta, K. Sudoh, M. Sasamata, and S. Yamagishi Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers Int J Clin Pharmacol Res 25 2005 41 46
2. S.C. Benson, H.A. Pershadsingh, and C.I. Ho Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity Hypertension 43 2004 993 1002
3. J.P. Habashi, D.P. Judge, and T.M. Holm Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome Science 312 2006 117 121
4. M.G. Keane, and R.E. Pyeritz Medical management of Marfan syndrome Circulation 117 2008 2802 2813
5. B.L. Loeys, U. Schwarze, and T. Holm Aneurysm syndromes caused by mutations in the TGF-beta receptor N Engl J Med 355 2006 788 798
6. S.S. Chaudhry, S.A. Cain, A. Morgan, S.L. Dallas, C.A. Shuttleworth, and C.M. Kielty Fibrillin-1 regulates the bioavailability of TGFbeta1 J Cell Biol 176 2007 355 367
7. Z. Isogai, R.N. Ono, and S. Ushiro Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein J Biol Chem 278 2003 2750 2757
8. E.R. Neptune, P.A. Frischmeyer, and D.E. Arking Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome Nat Genet 33 2003 407 411
9. Ng CM, Cheng A, Myers LA, et al. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 2004;114:1586-92.
10. A.H. Gradman Evolving understanding of the renin-angiotensin-aldosterone system: pathophysiology and targets for therapeutic intervention Am Heart J 157 6 Suppl 2009 S1 S6
11. H. Akazawa, N. Yasuda, and I. Komuro Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor Mol Cell Endocrinol 302 2009 140 147
12. Y. Zou, H. Akazawa, and Y. Qin Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II Nat Cell Biol 6 2004 499 506
13. D.S. Lim, S. Lutucuta, and P. Bachireddy Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy Circulation 103 2001 789 791
14. P. Lavoie, G. Robitaille, M. Agharazii, S. Ledbetter, M. Lebel, and R. Larivière Neutralization of transforming growth factor-beta attenuates hypertension and prevents renal injury in uremic rats J Hypertens 23 2005 1895 1903
15. T. Naito, T. Masaki, D.J. Nikolic-Paterson, C. Tanji, N. Yorioka, and N. Kohno Angiotensin II induces thrombospondin-1 production in human mesangial cells via p38 MAPK and JNK: a mechanism for activation of latent TGF-beta1 Am J Physiol Renal Physiol 286 2004 F278 F287
16. U. Seeland, A. Schäffer, and S. Selejan Effects of AT1- and beta-adrenergic receptor antagonists on TGF-beta1-induced fibrosis in transgenic mice Eur J Clin Invest 39 2009 851 859
17. J.R. Cook, H. Nistala, and F. Ramirez Drug-based therapies for vascular disease in Marfan syndrome: from mouse models to human patients Mt Sinai J Med 77 2010 366 373
18. R.V. Lacro, H.C. Dietz, and L.M. Wruck Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome Am Heart J 154 2007 624 631
19. F.I. Gambarin, V. Favalli, and A. Serio Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations J Cardiovasc Med (Hagerstown) 10 2009 354 362
20. T. Radonic, P. de Witte, and M.J. Baars Losartan therapy in adults with Marfan syndrome: study protocol of the multi-center randomized controlled COMPARE trial Trials 11 2010 3
21. D. Detaint, P. Aegerter, and F. Tubach Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome Arch Cardiovasc Dis 103 2010 317 325
22. K. Möberg, S. De Nobele, and D. Devos The Ghent Marfan Trial - a randomized, double-blind placebo controlled trial with losartan in Marfan patients treated with β-blockers Int J Cardiol 2011 Jan 14 [Epub ahead of print]
23. L.J. Ma, C. Marcantoni, M.F. Linton, S. Fazio, and A.B. Fogo Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats Kidney Int 59 2001 1899 1910
24. T. Takahashi, H. Ono, Y. Ono, T. Ishimitsu, and H. Matsuoka Combination therapy with telmisartan and spironolactone alleviates L-NAME exacerbated nephrosclerosis with an increase in PPAR-gamma and decrease in TGF-beta(1) Int Heart J 48 2007 637 647
25. Y. Yao, R. Zou, and X. Liu Telmisartan but not valsartan inhibits TGF-beta-mediated accumulation of extracellular matrix via activation of PPARgamma J Huazhong Univ Sci Technolog Med Sci 28 2008 543 548
26. R. Zou, G. Xu, and X.C. Liu PPARgamma agonists inhibit TGF-beta-PKA signaling in glomerulosclerosis Acta Pharmacol Sin 31 2010 43 50
27. A.P. Lakshmanan, K. Watanabe, and R.A. Thandavarayan Telmisartan attenuates oxidative stress and renal fibrosis in streptozotocin induced diabetic mice with the alteration of angiotensin-(1-7) mas receptor expression associated with its PPAR-γ agonist action Free Radic Res 45 2011 575 584
28. Y. Maejima, H. Okada, and G. Haraguchi Telmisartan, a unique ARB, improves left ventricular remodeling of infarcted heart by activating PPAR gamma Lab Invest 91 2011 932 944
29. A.D. Everett, A. Tufro-McReddie, A. Fisher, and R.A. Gomez Angiotensin receptor regulates cardiac hypertrophy and transforming growth factor-beta 1 expression Hypertension 23 1994 587 592
30. G. Wolf, F.N. Ziyadeh, and R.A. Stahl Angiotensin II stimulates expression of transforming growth factor beta receptor type II in cultured mouse proximal tubular cells J Mol Med (Berl) 77 1999 556 564
31. N. Fukuda, W.Y. Hu, and A. Kubo Angiotensin II upregulates transforming growth factor-beta type I receptor on rat vascular smooth muscle cells Am J Hypertens 13 2000 191 198
32. A.J. Coats, and L.G. Shewan Ethics in the authorship and publishing of scientific articles Int J Cardio 153 2011 239-40